Hemi Pharma semaglutide 5mg: what it is and why it matters in the UK

You found "Hemi Pharma semaglutide 5mg", here is what that product actually is

Picture this: you have been reading about Wegovy, seen the price, and then spotted what looks like a much cheaper alternative labelled "Hemi Pharma semaglutide 5mg" on a marketplace or Telegram channel. It is presented as the same active ingredient at a fraction of the cost. The framing sounds plausible.

Hemi Pharma is not a UK-licensed pharmaceutical manufacturer. The semaglutide it produces is a compounded or otherwise unlicensed preparation, meaning it has not gone through the MHRA's approval process for quality, purity, or efficacy in the context of weight management. The MHRA licenses medicines in the UK, not the European Medicines Agency, and an unlicensed product falls outside those protections regardless of what its label claims.

The "5mg" figure is also worth unpicking. If you want to understand what a legitimate semaglutide 5mg formulation actually involves and how it fits into a licensed context, that page sets out the details clearly. The licensed Wegovy injection schedule (starting at 0.25 mg and moving up through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, with a maximum of 7.2 mg now available) does not include a 5 mg dose. You can read about how the Wegovy dose schedule works in detail. A "5 mg" label suggests either a different concentration system, a compounded formulation, or a mislabelled product, none of which is reassuring when the medicine in question is injected. The MHRA has warned publicly about counterfeit and contaminated pens seized in the UK, including some that were found to contain insulin rather than the claimed active ingredient, with hospitalisations resulting.

Reporting concerns about suspect sellers is straightforward via the MHRA's Yellow Card scheme, which also covers suspected counterfeit medicines.

Why "same ingredient, lower price" is not the same as "safe and equivalent"

It is understandable to ask whether the active molecule is simply semaglutide regardless of who makes it. In principle, generic medicines work on exactly that logic. But generic medicines still go through regulatory approval, a manufacturer demonstrates that their product is bioequivalent to the reference medicine, manufactured to verified standards, and stable in its stated form. That process is the protection, not just the ingredient name on the label.

Compounded semaglutide bypasses that process. There is no requirement for a compounding supplier to demonstrate consistency between batches, sterility, or correct concentration. An injectable that is slightly too concentrated, contaminated with particulates, or improperly stored during shipping can cause serious harm. The risk is not theoretical: enforcement action in 2025 included the seizure of approximately 20 million doses of illegally traded weight-loss medicines worth around £45 million, and the first illicit UK manufacturing site producing counterfeit tirzepatide pens was raided in Northampton.

For context on what legitimate private treatment costs and what it includes, the Wegovy cost page sets out the market honestly, including why prices shifted significantly after Eli Lilly's list-price change in 2025. A price that looks dramatically lower than everything else is a signal worth pausing on, not celebrating.

If you are concerned about a product you have already received, speak to your GP or contact the MHRA. Do not inject anything you cannot trace to a GPhC-registered pharmacy.

What a licensed semaglutide programme actually looks like

Licensed Wegovy begins at 0.25 mg, a dose whose job is to let your body adjust gradually, reducing the nausea that semaglutide can cause in the early weeks. The schedule moves up roughly every four weeks, guided by a prescriber who checks how you are tolerating each level. Reaching the 2.4 mg maintenance dose typically takes around five months; the 7.2 mg option, approved by the MHRA in April 2026 as a dedicated single-dose pen, is for adults with a BMI of 30 or above and is the highest available step.

STEP 1, the pivotal clinical trial published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at 2.4 mg semaglutide. That evidence base exists because the trial used a defined, verified formulation under controlled conditions, not a compounded analogue at an unvalidated concentration.

The semaglutide dosing overview covers each step in plain terms. If you want to understand where a specific earlier dose fits, the 1 mg semaglutide page explains what that stage is for. Every change in a licensed programme is reviewed by a prescriber, it is not self-directed, and that oversight is part of the safety structure, not a formality.

Eligibility for licensed Wegovy requires a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure or type 2 diabetes. You can explore what the licensed weight-loss options look like on the weight-loss treatment overview.

What to do if you were considering Hemi Pharma semaglutide

If you found Hemi Pharma semaglutide 5mg because you want to lose weight and Wegovy felt out of reach, that is a completely reasonable starting point. Plenty of people find the private cost a stretch, or feel uncertain whether they will qualify, and look for alternatives. That frustration is real.

The practical path forward is a clinical consultation. At nume, a GPhC-registered Independent Prescriber reads your answers the same day, not software, a named clinician. If you order before noon on a working day and your treatment is approved, it goes out the same afternoon with DPD, arriving the next working day in plain packaging. That 12pm window before the school run is firm, which is why many patients submit their consultation first thing in the morning. You can check your eligibility and see current treatment options on the consultation page, where the full pricing is shown clearly.

The NHS England guidance on weight-management injections also sets out the licensed medicines, eligibility criteria, and what to expect from any legitimate programme, worth reading before making a decision either way.